A 16% lower adjusted risk in recurrent Clostridioides difficile infections was found in 2018 compared with 2013 across diverse US sites part of the CDC’s Emerging Infections Program. Risk of recurrent ...

The researchers wrote that their findings showcase the need for close monitoring of patients and for effective treatments for those with recurrent infection, which occurs in 15%-30% of all patients ...

Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...

Treatment with ridinilazone was found to significantly decrease the rate of recurrent Clostridioides difficile infection (CDI) compared with vancomycin. Treatment with ridinilazone was found to ...

REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff ...

A common practice for treating patients with gastrointestinal conditions has been revised by the American Gastroenterological Association, it announced Feb. 21. The group has expanded its ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Two ...

Please provide your email address to receive an email when new articles are posted on . Rebyota was effective in real-world analyses, with results consistent with the PUNCH CD3 trial. Rebyota was also ...

AstraZeneca (AZN) announced an update on their ongoing clinical study.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed ...

For the first time ever, Ferring and Rebiotix, a Ferring Company, will present landmark Phase 3 efficacy and safety data from the PUNCH™ CD3 trial evaluating investigational microbiota-based live ...

C. difficile infection recurrence rates were numerically lower with vancomycin than with placebo, though the difference was not significant. However, the results could be clinically meaningful, an ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Jessica R. Allegretti, MD, MPH, spoke with Healio about ...